Novartis to assist Australian Government with initial supply of hydroxychloroquine
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. The supply is part of a global commitment by Novartis to donate doses of hydroxychloroquine where it is supported by local regulatory authorities for use in COVID-19 infected patients.
For further information about what Novartis is doing globally, visit our global statement.